HALOZYME THERAPEUTICS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.4B | $1.0B | $829.3M | $660.1M | $443.3M |
| Cost of revenue | $228.8M | $159.4M | $192.4M | $139.3M | $81.4M |
| Selling, general & administrative | $207.1M | $154.3M | $149.2M | $143.5M | $50.3M |
| Research and development | $81.5M | $79.0M | $76.4M | $66.6M | $35.7M |
| Operating income | $469.0M | $551.5M | $337.6M | $267.5M | $275.9M |
| Interest expense | $18.1M | $18.1M | $18.8M | $16.9M | $7.5M |
| Pretax income | $466.9M | $557.1M | $348.3M | $248.9M | $248.5M |
| Income tax expense | $150.0M | $113.0M | $66.7M | $46.8M | -$154.2M |
| Net income | $316.9M | $444.1M | $281.6M | $202.1M | $402.7M |
| Balance Sheet | |||||
| Cash and equivalents | $133.8M | $115.8M | $118.4M | $234.2M | $118.7M |
| Current assets | $825.2M | $1.1B | $746.4M | $739.0M | $926.3M |
| Total assets | $2.5B | $2.1B | $1.7B | $1.8B | $1.1B |
| Current liabilities | $177.1M | $139.1M | $112.5M | $130.8M | $117.1M |
| Total liabilities | $2.5B | $1.7B | $1.6B | $1.7B | — |
| Total debt | $2.2B | $1.5B | $1.5B | $1.5B | $895.9M |
| Stockholders' equity | $48.8M | $363.8M | $83.8M | $169.8M | $197.0M |
| Cash Flow Statement | |||||
| Cash from operations | $651.6M | $479.1M | $388.6M | $240.1M | $299.4M |
| Depreciation and amortization | $11.4M | $10.3M | $11.1M | $6.5M | $3.0M |
| Stock-based compensation | $51.6M | $43.4M | $36.6M | $24.4M | $20.8M |
| Capital expenditure | $7.0M | $10.7M | $15.3M | $4.8M | $1.5M |
| Free cash flow | $644.6M | $468.4M | $373.3M | $235.3M | $298.0M |
| Share repurchases | $342.4M | $250.0M | $402.4M | $200.0M | $350.1M |
Shares outstanding 118.6M · Free float 91.5%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.